Marleen E. Jansen

Feb 10, 2023 | mdpi.com | Patrick C. Souverein |Susanne Vijverberg |Marleen E. Jansen |Tessel Rigter

Abstract:Pharmacogenomic testing is a method to prevent adverse drug reactions. Pharmacogenomics could be relevant to optimize statin treatment, by identifying patients at high risk for adverse drug reactions. We aim to investigate the clinical validity and utility of pre-emptive pharmacogenomics screening in primary care, with SLCO1B1 c.521T>C as a risk factor for statin-induced adverse drug reactions.